Although it’s possible that the FDA approval for the interim look can provide some boost and is the showstopper for any AXAL deal, I doubt it is the reason for an absence of any monetary deals.
Management has been talking about possibility of partnerships, deals etc. for more than a year now. Reality is out there in the open for all to see - whether it is in the pps/MC or key people leaving the company.
News 
Market Data 
Discover 
AI
